TransMedics Group (NASDAQ: TMDX) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for allegedly misleading investors and failing to disclose critical issues during the Class Period from February 28, 2023, to January 10, 2025 [1][3]. Company Overview - TransMedics Group, Inc. is a medical technology company based in Andover, Massachusetts, specializing in transplant services, including its Organ Care System (OCS), which is a portable organ preservation system [2]. Allegations - The lawsuit claims that TransMedics engaged in unethical practices, including using kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [3]. - It is also alleged that the company concealed safety issues and lacked proper safety oversight within its operations [3]. Impact of Revelations - On February 21, 2024, U.S. Rep. Paul Gosar accused TransMedics of misappropriating corporate resources, leading to a stock price drop of $2.18 per share (2.5%) to close at $84.81 on February 22, 2024 [4]. - Following a report from Scorpion Capital on January 10, 2025, which accused TransMedics of overbilling hospitals and providing rejected organs, the stock fell by $3.74 per share (5%) to close at $68.81, and then further declined by $4.76 per share (6.9%) to close at $64.05 on January 13, 2025 [5].